All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

NT-I7 After CAR T-Cell Therapy Enhances CAR T Factors in R/R DLBCL

October 7th 2024

NT-I7 with CAR T-cell therapy demonstrated an 81.1% objective response rate in relapsed DLBCL patients and a manageable safety profile.

Gotistobart Plus Pembrolizumab Shows Activity in Platinum-Resistant Ovarian Cancer

October 7th 2024

Gotistobart plus pembrolizumab demonstrated antitumor activity and a manageable safety profile in platinum-resistant ovarian cancer.

Cigall Kadoch, PhD, Wins Prestigious Blavatnik National Award

October 7th 2024

Cigall Kadoch, PhD, has been named as the Laureate of the Blavatnik National Awards for Young Scientists in the field of life sciences.

Health Canada Expands Indication for Illuccix Diagnostic Kit for PSMA-Targeted Radioligand Therapy in mCRPC

October 7th 2024

Illuccix has been approved in Canada for the selection of patients with mCRPC eligible for treatment with PSMA1-targeted radionuclide therapy.

ELVN-001 Appears Safe and Effective in Relapsed/Refractory CML

October 7th 2024

ELVN-001 generated prolonged signals of clinical activity with a tolerable safety profile in patients with TKI-relapsed, -refractory, or -intolerant CML.

Next Generation of CDK Inhibitors Are Breaking Ground in HER2– Breast Cancer

October 7th 2024

Joseph A. Sparano, MD, details the next generation of CDK inhibitors such as BLU-222 targeting CDK2 and PF-07220060 targeting CDK4.

Neoadjuvant Pertuzumab Biosimilar Plus Trastuzumab/Docetaxel Meets pCR End Point in HER2+ Breast Cancer

October 7th 2024

HLX11—a pertuzumab biosimilar—plus trastuzumab/docetaxel met the pCR end point in a phase 3 trial in early or locally advanced HER2-positive breast cancer.

Emavusertib Plus Ibrutinib Is Under Investigation in the TakeAim Trial in PCNSL

October 7th 2024

Grzegorz S. Nowakowski, MD, discusses the methods and objectives of the part B expansion portion of the TakeAim Lymphoma study in patients with PCNSL.

The Role of Biomarkers in the Treatment of Metastatic NSCLC

October 7th 2024

Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC

October 6th 2024

Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.

The OncFive: Top Oncology Articles for the Week of 9/29

October 5th 2024

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

Research Seeks to Establish the Efficacy of Minimally Invasive Breast Cancer Procedures and Tests

October 5th 2024

Yuan Yuan, MD, PhD, discusses the management of node-positive breast cancer and the need for guidance surrounding the use of ctDNA in breast cancer.

OncLive’s September Roundup of Key FDA Approvals in Oncology

October 4th 2024

Here is your snapshot of all treatment options that the FDA approved in September 2024.

Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR+ NSCLC

October 4th 2024

Isabel Preeshagul, DO, MBS, discusses considerations for treatment selection in the first and second line for patients with EGFR-mutated NSCLC.

Novel Anti-Estrogen Therapies Are Poised to Expand Treatment Options in Advanced ER+ Breast Cancer

October 4th 2024

Seth Wander, MD, PhD on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer.

Criteria for Cancer Clinical Trials and Treatment Regimens Place Patients of African and Middle Eastern Ancestry at a Disadvantage Due to Natural Blood Test Variability, Study Finds

October 4th 2024

Clinical trials may be inappropriately excluding some people with "Duffy-null phenotype," a trait found in people of African or Middle Eastern descent.

MAGIC-G1 Study Provides Updated Findings With MTX110 in Recurrent Glioblastoma

October 4th 2024

An update on PFS and OS data from the phase 1 MAGIC-G1 study of MTX110 in recurrent glioblastoma has been released.

FDA Approves Cologuard Plus for Adults at Average Risk for CRC

October 4th 2024

The FDA has approved Cologuard Plus, a next-generation multitarget stool DNA test, for adults at least 45 years of age who are at average risk for CRC.

Park and Leyfman Hope to Advance Mission of MedNews Week Through Collaboration With OncLive

October 4th 2024

Chandler Park, MD, FACP, and Yan Leyfman, MD, discuss their partnership with OncLive and future goals for MedNews Week.

Emavusertib-Focused Research Is Poised to Expand the PCNSL Treatment Paradigm

October 4th 2024

Grzegorz S. Nowakowski, MD, discusses the unique mechanism of action of emavusertib and highlights the phase 1/2 TakeAim Lymphoma trial in PCNSL.